Glythera-PATH collaboration aims at better pneumococcal vaccines
This article was originally published in Scrip
Executive Summary
The UK biotech firm Glythera has entered into a research collaboration with non-profit organisation PATH in an effort to develop more efficacious conjugate vaccines against pneumococcal disease.